Disclosed herein are improved methods for the preparation of oseltamivir, and intermediates useful thereto.

The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, containing a compound represented by Formula (I), an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof.

The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, containing a compound represented by Formula (I), an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof.

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing a substituted bicyclo[1.1.1]pentane using a Group VII or Group IX transition metal compound.

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing a substituted bicyclo[1.1.1]pentane using a Group VII or Group IX transition metal compound.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.